On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development.
The presentations from the 4th International Workshop on Clin. Pharm. of TB Drugs are available [click here].
Key abstracts from ICAAC were:
| Authors | Abstract Title |
|
Pyrazinamide Increases the Early Bactericidal Activity of TMC207 and PA-824 in Patients with Newly Diagnosed, Smear-positive Pulmonary Tuberculosis |
|
Phase 2 Trial of a Novel 3-Drug Regimen for Both MDR and Drug Sensitive (DS) TB |
|
Novel TMC207-containing Regimens Have Sterilizing Activity In Murine Tuberculosis |
|
SAR of Riminophenazine Class and Discovery of New Anti-tuberculosis Agents Active Against Multidrug-Resistant Tuberculosis |
|
Clofazimine Analogs with Superior Efficacy against Experimental Tuberculosis and Reduced Potential
for Tissue Discoloration |
|
Anti-tubercular Clofazimine Analogs that Demonstrate a Range of Tissue Distribution Patterns Following Eight Weeks Dosing to Mice |
|
Extensively Drug-resistant Tuberculosis (XDR-TB) Treated with Daily/ Intermittent Linezolid |
|
Tolerability of Moxifloxacin as Part of Anti-Tuberculous Treatment |
Additional TB R&D News:
Epistem successfully completes first-round testing of TB diagnostic device
Open Innovation Drug Discovery [Actual Website]
Drug-Evading Tuberculosis Shows Rising Superbug Threat in China